As of 2025-09-19, the EV/EBITDA ratio of Chinook Therapeutics Inc (KDNY) is -11.89. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. KDNY's latest enterprise value is 2,773.05 mil USD. KDNY's TTM EBITDA according to its financial statements is -233.23 mil USD. Dividing these 2 quantities gives us the above KDNY EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.7x - 14.7x | 13.9x |
| Forward P/E multiples | 16.6x - 34.2x | 19.2x |
| Fair Price | (52.02) - (45.98) | (51.99) |
| Upside | -228.8% - -213.8% | -228.7% |
| Date | EV/EBITDA |